Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 8, 1995

Primary Completion Date

April 1, 2024

Study Completion Date

April 1, 2024

Conditions
Congenital Adrenal Hyperplasia (CAH)
Interventions
DRUG

Fludrocortisone

Mineralocorticoid needed to replace aldosterone deficiency. Patients will continue to receive an optimal fludrocortisone dose

DRUG

Hydrocortisone

Glucocorticoid needed to replace cortisol deficiency. Reduced hydrocortisone dose might normalize the growth and adult stature of children with congenital adrenal hyperplasia

DRUG

Letrozole

Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.

DRUG

Flutamide

Non steroidal anti-androgen that prevents the action of androgens by blocking receptor sites in target tissue. It may also produce changes in testosterone and estradiol

DRUG

Testolactone

Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

NCT00001521 - Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia | Biotech Hunter | Biotech Hunter